What Researchers Did
Researchers reported on a single 22-year-old patient who developed memory loss after receiving CAR-T cell therapy for Burkitt lymphoma.
What They Found
The patient experienced memory loss one month after CAR-T therapy, and two months of rehabilitation and hyperbaric oxygen therapy did not improve symptoms. After a period of decline following oxiracetam withdrawal, the patient maintained memory gains at 6 and 12 months when treated with sodium oligomannate, alone or combined with rivastigmine.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
As a case report involving only one patient, these findings cannot be generalized to a larger population.